Clinical Trial

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy and safety of the combined treatment with Sacituzumab Tirumotecan in patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT07128693
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 60 participants
Start Date 2025-09
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-19